.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FX07_Blinatumomab.Blinatumomab

Information

Blinatumomab is a bispecific T-cell engager (BiTE) monoclonal antibody used in the treatment of acute lymphoblastic leukemia (ALL). It binds CD19 on B-cells and CD3 on T-cells, directing cytotoxic T-cells to kill malignant B-cells. Blinatumomab is approved for the treatment of relapsed or refractory B-cell precursor ALL in adults and children.

Pharmacokinetics

Pharmacokinetic parameters reported in adults (18–77 years) with relapsed or refractory B-cell precursor acute lymphoblastic leukemia treated with intravenous blinatumomab. Parameters obtained at steady-state during continuous intravenous infusion.

References

1. Clements, JD, et al., & Doshi, S (2020). Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies. Clinical pharmacokinetics 59(4) 463–474. DOI:10.1007/s40262-019-00823-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31679130

2. Zhu, M, et al., & Doshi, S (2016). Blinatumomab, a Bispecific T-cell Engager (BiTE(®)) for CD-19 Targeted Cancer Immunotherapy: Clinical Pharmacology and Its Implications. Clinical pharmacokinetics 55(10) 1271–1288. DOI:10.1007/s40262-016-0405-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27209293

3. Kaplan, JB, et al., & Giles, FJ (2015). Blinatumomab for the treatment of acute lymphoblastic leukemia. Investigational new drugs 33(6) 1271–1279. DOI:10.1007/s10637-015-0289-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26383529

Revisions

• 06/2025 initial generated model